Book this year's International QA Conference now.
More informationJoin our pre-conference events - now with a discount!
More informationJoin the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More information5th September 2024
MHRA - Pharmacovigilance following agreement of the Windsor Framework
This guidance is designed to provide information on the implementation of changes to pharmacovigilance for medicines authorised in the UK following the agreement of the Windsor Framework.
These changes will be implemented from 1 January 2025.
This guidance should be used in conjunction with the MHRA’s guidance on the Windsor Framework including UK-wide licensing for human medicines, and labelling and packaging guidance.